Li Jian
Department of General Surgery, The Third Hospital of Mianyang, Sichuan Mental Health Center Mianyang 621000, Sichuan, China.
Am J Cancer Res. 2021 Jul 15;11(7):3406-3424. eCollection 2021.
Increasing evidence has linked claudins to signal transduction and tumorigenesis. The expression of claudins is frequently dysregulated in the context of neoplastic transformation, suggesting their promise as biomarkers for diagnosis and prognosis or targets for treatment. Claudin binders (Clostridium perfringens enterotoxin and monoclonal antibody) have been tested in preclinical experiments, and some of them have progressed into clinical trials involving patients with certain cancers. However, the clinical development of many of these agents has not advanced to clinical applications. Herein, I review the current status of preclinical and clinical investigations of agents targeting claudins for diagnosis, prognosis and therapy. I also discuss the potential of combining claudin binders with other currently approved therapeutic agents.
越来越多的证据表明，紧密连接蛋白与信号转导和肿瘤发生有关。在肿瘤转化过程中，紧密连接蛋白的表达常常失调，这表明它们有望作为诊断和预后的生物标志物或治疗靶点。紧密连接蛋白结合剂（产气荚膜梭菌肠毒素和单克隆抗体）已在临床前实验中进行了测试，其中一些已进入涉及某些癌症患者的临床试验。然而，许多此类药物的临床开发尚未推进到临床应用阶段。在此，我综述了针对紧密连接蛋白进行诊断、预后和治疗的药物的临床前和临床研究现状。我还讨论了将紧密连接蛋白结合剂与其他目前已获批的治疗药物联合使用的潜力。
